What are the opening hours?

Monday 8am - 6pm Tuesday 8am - 6pm Wednesday 8am - 6pm Thursday 8am - 6pm Friday 8am - 6pm

Beyondbmi, Dublin (2026)

10/03/2026

Dr Harriet Treacy, our Founder of BeyondBMI, reflects on how obesity care has evolved on the IMAGE Podcast.

For many years, the dominant message was simple: eat less and move more. At the time, healthcare professionals had limited medical tools available.

In recent years, that has begun to change. The emergence of treatments such as GLP-1 medications and newer dual-agonist therapies has expanded the medical toolbox and broadened how we can support patients.

Understanding obesity as a chronic disease, rather than a lifestyle choice, has been a crucial shift. As scientific understanding has grown, so too have the treatment options available.

Obesity medicine continues to evolve — and so does the way we care for patients.

🎙 Listen to the full conversation on the IMAGE The Check-in Podcast

09/03/2026

On 🎙️ Dr Harriet Treacy, Founder of Beyond BMI, speaks about the importance of education in obesity care

Obesity is not a short term weight issue, It is a chronic disease that requires ongoing management 🧠

Quick fixes and six week plans set people up for cycles of shame and regain Sustainable care means honest conversations and long term medical support 🤝

Health is not static 🔄 Obesity treatment should not be either 🌱

Have you ever felt like you were sold the dream of a 6 or 12 week quick fix diet plan only to find yourself regaining weight weeks later?

🎙️ Full episode now live

06/03/2026

The Beyondbmi team hit Token for another team day - and once again, it was all about connection, laughter, and a little friendly competition 🎮✨

We discovered some unexpected talents along the way…

🎸 Guitar Hero revealed Brian’s secret guitar skills, while Andriy proved to be a natural-born rockstar

🏎️ Mario Kart took us straight back to our childhoods (with plenty of competitive spirit!)

💃 Dance Battle added a bit of cardio, a lot of laughter, and some unforgettable moves from the whole team

At Beyondbmi, teamwork isn’t just what we do, it’s who we are.

Different disciplines, one mission: putting our members at the heart of everything we do ❤️

💙 Huge thanks to the Beyondbmi team who made the day possible, moments like these remind us how powerful human connection really is.

05/03/2026

On the IMAGE Podcast, Founder of Beyondbmi, Dr Harriet Treacy explains what actually happens in the brain when someone takes a GLP 1 based treatment.

GLP 1 is a hormone we naturally produce when we eat. It signals fullness to the brain. However, in its natural form, it breaks down within minutes

GLP 1 medications are designed to last longer in the body. They cross into the brain and act on appetite centres, helping to regulate hunger and satiety for five to seven days. This is why they are given as once weekly injections 💉

Understanding how these treatments work helps shift the conversation away from willpower and towards biology

Obesity is regulated by complex brain pathways. Effective treatment targets those pathways

🎙 Listen to the full discussion on the IMAGE Podcast

04/03/2026

Today is World Obesity Day.

As Dr Joe O’Brien, Head of Psychology at Beyondbmi, says:

“The impact goes beyond physical health alone.”

Eating habits are shaped by far more than conscious choice. Experiences such as trauma, shame, or growing up with a strong focus on body weight can influence someone’s relationship with food — and how they feel about themselves.

“These experiences are not a coincidence. They matter.”

If we only treat the body and ignore the brain, we miss the opportunity to treat the person as a whole.

Obesity care should always include psychology.
Because people are more than their weight — and care should reflect that.

03/03/2026

“By 2035, half of the world’s population - around 4 billion people- are expected to be living with overweight or obesity.” -

Tomorrow, March 4th is World Obesity Day, a reminder that we all have a role to help change the story on obesity.

At Beyondbmi, that means recognising obesity for what it is: a chronic, biologically regulated disease, not a short-term problem to fix.

Changing the story starts with moving away from blame and quick fixes, and towards long-term, evidence-based care and support.

Everyone has their own reasons to change the story of obesity.

If you are living with overweight or obesity, what would you like to change in your own health journey?

23/02/2026

If you and someone else started the same GLP-1 medication, but had very different results - that doesn’t mean you did anything wrong.

In real life (and in clinical trials), response to GLP-1 medication varies a lot.

Some people lose a significant amount of weight, some lose less, and a small group sees minimal change - even when they’re doing “all the right things.”

Why can outcomes differ so much?
Because obesity isn’t one single condition. It’s a heterogeneous disease - meaning the drivers can vary from person to person.

Two people can have different:
✅ metabolic phenotype (how the body stores and uses energy)
✅ insulin resistance / glucose regulation
✅ hormonal signalling and appetite regulation
✅ sleep disruption, stress physiology, medications
✅ co-morbidities (e.g. PCOS, T2D, depression)
✅ genetics and family risk

GLP-1 medications don’t work in just one way. They influence appetite, fullness, digestion, and metabolic hormones. Because each person’s physiology is different, this can change how powerful the effect feels and how long it lasts. These signals can feel stronger in some people than others, and the effect can last differently over time

The clinical takeaway:
This is why obesity care is moving toward individualised, phenotype-guided treatment - not “one plan for everyone.”

So if your outcome didn’t match someone else’s… please hear this clearly:

It’s not a character flaw. It’s biological variation.

And it’s exactly why ongoing, structured medical care matters.

19/02/2026

If weight management has felt harder without support - that’s not a willpower problem.

Obesity is a multi-factorial chronic disease and long-term outcomes often depend on continuity of care, not “more motivation.”

GLP-1 medications support obesity treatment and weight management by influencing appetite, satiety (fullness), and hunger signalling through gut–brain pathways, alongside other important metabolic effects.

When support is absent, this can influence our physiology and biology.

Modern obesity care is therefore designed around ongoing, multidisciplinary support rather than one-off interventions.

That’s why wrap-around care (an MDT) matters.

MDT = a multidisciplinary team, which may include:

👩‍⚕️ Medical clinician (GP / Obesity Specialist)

Assesses metabolic risk, medications, long-term treatment plan and follow-up.

🥗 Registered Dietitian

Supports nutrition in a way that protects your health, energy and eating behaviours without dieting extremes.

🧠 Behavioural Health Practitioner/Health Coaches

Helps support your key pillars of health; from sleep disruption and emotional load, to habit formation and relationship with food *without shame-based approaches*.

🏃‍♀️ Clinical Nurse Specialist

Supports you when you’re on the go between medical consults with side-effect management and changing medical needs

You don’t need to “try harder.”

You deserve the right multidisciplinary team around you.

13/02/2026

Vol.3 What a plateau tells us about obesity.

When weight stabilises at a plateau, it’s easy to assume something has gone wrong.

This review by Purnell & le Roux explains that what’s happening is deeper, and it’s happening in the brain.

Body fat mass is regulated by the hypothalamus, a control centre in the brain that continuously integrates signals from fat tissue and the gut to manage hunger, fullness, and how much energy the body uses.

Hormones like leptin signal how much fat mass is being carried. Gut hormones like GLP-1 signal satiety. Together, these signals allow the brain to defend a body-fat “set point.”

In obesity, this system becomes disrupted.

The brain defends a higher fat mass than is healthy, often generating persistent hunger and reduced satiety, even when energy stores are already sufficient.

This is why obesity cannot be understood as a problem of willpower. It reflects altered physiology, not lack of effort.

Effective treatments work because they target these subcortical pathways, allowing the brain to regulate appetite and energy balance differently.

A plateau, then, reflects the point where the brain’s regulatory system has stabilised under the current treatment.

Understanding this biology is key to moving away from stigma, and toward medical care.

🧬The study: Purnell, J.Q. & le Roux, C.W. (2024). “Hypothalamic control of body fat mass by food intake: The key to understanding why obesity should be treated as a disease”. Diabetes, Obesity and Metabolism, 26(Suppl 2), pp. 3–12. DOI: https://doi.org/10.1111/dom.15478

11/02/2026

Vol.2 Why weight-loss plateaus happen.

If weight loss slowed or stabilised despite treatment, that experience is very common.

A review by Purnell & Le Roux explain that body fat is biologically defended by a homeostatic set point, an internal balance maintained by hormonal signals between fat tissue, the gut, and the brain.

In obesity, this balance shifts upwards due to leptin resistance.

Fat tissue sends a weaker signal about stored energy, and the body responds by:

increasing hunger
reducing fullness
conserving energy
This is why weight loss through calorie restriction alone is rarely sustained.

As fat mass falls, the body activates predictable adaptive responses designed to restore weight toward its previous level.

Medical and surgical obesity treatments work differently.

They act on these biological signals, improving satiety signalling and reducing persistent hunger and “food noise”, allowing weight to stabilise at a lower level.

A plateau is not a failure of effort.

It reflects the point where current treatment has reached its maximum biological effect.

Long-term weight management requires ongoing treatment to maintain these physiological changes.

🧬The study: Purnell, J.Q. & Le Roux, C.W. (2026). “Metabolic and appetitive regulation of adipocyte mass during treatment of obesity”. Journal of Internal Medicine, 299(1), pp.66–78. DOI: 10.1111/joim.70045

09/02/2026

Professor Carel le Roux explains what a “weight-loss plateau” really is.

A weight-loss plateau is biological homeostasis - a new normal. This is the biological point where the disease of obesity is controlled by the treatment we have. The more effective the treatment, the lower the fat mass at this balance point.

For most people, the weight reached here is higher than they would like, but it represents the best balance the body can achieve biologically with that treatment.

At this balance point, people often feel:

- less full
- more hungry
- more preoccupied with food
- able to eat more

And yet, their weight remains stable as long as treatment continues.

Attempts to force further loss through calorie restriction or excessive exercise usually move the body out of balance in ways that cannot be sustained.

To change the balance point itself, treatment must change, through newer therapies, combination approaches, or surgery.

21/01/2026

What happens when people stop weight loss medication?

Firstly… Let’s set the record straight….

‼️THIS STUDY FROM THE BMJ IS NOT NEW INFORMATION‼️

Anyone in the obesity field has known that obesity is a chronic relapsing disease and that GLP-1 medications were never intended to be taken for short periods.

But…. for those of you that heard about the study and want us to decode the findings, read below 👇

A systematic review and meta-analysis published in The BMJ (7th January 2026) examined weight regain after stopping weight management medications across 37 studies and 9,341 adults.

Key findings:

• People regained weight at an average rate of 0.4 kg/month after stopping medication

• After stopping semaglutide/tirzepatide, weight regain was faster (0.8 kg/month)

• Weight and cardiometabolic markers (blood sugar, blood pressure, cholesterol, triglycerides) were projected were projected to return close to baseline within ~1.4 years

This reinforces an already well known clinical reality: Obesity is a chronic, relapsing condition and long-term outcomes often require ongoing support and structured care not short-term interventions.

Hype over!

📌 Source: West S. et al., The BMJ, 2026.

Beyondbmi

10/03/2026

09/03/2026

06/03/2026

05/03/2026

04/03/2026

03/03/2026

23/02/2026

19/02/2026

13/02/2026

11/02/2026

09/02/2026

21/01/2026

Address

Opening Hours

Website

Alerts

Contact The Practice

Shortcuts

Featured

Share

Category

Monday	8am - 6pm
Tuesday	8am - 6pm
Wednesday	8am - 6pm
Thursday	8am - 6pm
Friday	8am - 6pm